Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

BACKGROUND: We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma (a/mRCC). METHODS: In the COMPARZ study, patients were randomized (1:1) to rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Xinan, Jin, Jie, He, Zhisong, Huang, Yiran, Zhou, Aiping, Wang, Jinwan, Ren, Xiubao, Ye, Dingwei, Zhang, Xu, Qin, Shukui, Zhou, Fangjian, Wang, Binhui, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071746/
https://www.ncbi.nlm.nih.gov/pubmed/32171288
http://dx.doi.org/10.1186/s12885-020-6708-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071746/
https://www.ncbi.nlm.nih.gov/pubmed/32171288
http://dx.doi.org/10.1186/s12885-020-6708-8

Ejemplares similares